GLUE
Price
$4.77
Change
+$0.03 (+0.63%)
Updated
Jun 25 closing price
Capitalization
293.4M
42 days until earnings call
RXRX
Price
$5.16
Change
-$0.06 (-1.15%)
Updated
Jun 25 closing price
Capitalization
2.1B
47 days until earnings call
Interact to see
Advertisement

GLUE vs RXRX

Header iconGLUE vs RXRX Comparison
Open Charts GLUE vs RXRXBanner chart's image
Monte Rosa Therapeutics
Price$4.77
Change+$0.03 (+0.63%)
Volume$405.57K
Capitalization293.4M
Recursion Pharmaceuticals
Price$5.16
Change-$0.06 (-1.15%)
Volume$20.93M
Capitalization2.1B
GLUE vs RXRX Comparison Chart in %
Loading...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLUE vs. RXRX commentary
Jun 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLUE is a StrongBuy and RXRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 26, 2025
Stock price -- (GLUE: $4.77 vs. RXRX: $5.16)
Brand notoriety: GLUE and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLUE: 94% vs. RXRX: 87%
Market capitalization -- GLUE: $293.4M vs. RXRX: $2.1B
GLUE [@Biotechnology] is valued at $293.4M. RXRX’s [@Biotechnology] market capitalization is $2.1B. The market cap for tickers in the [@Biotechnology] industry ranges from $312.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLUE’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • GLUE’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, both GLUE and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLUE’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • GLUE’s TA Score: 5 bullish, 5 bearish.
  • RXRX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than GLUE.

Price Growth

GLUE (@Biotechnology) experienced а +6.24% price change this week, while RXRX (@Biotechnology) price change was +0.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.95%. For the same industry, the average monthly price growth was +31.79%, and the average quarterly price growth was +15.79%.

Reported Earning Dates

GLUE is expected to report earnings on Aug 07, 2025.

RXRX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+1.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.1B) has a higher market cap than GLUE($293M). RXRX YTD gains are higher at: -23.669 vs. GLUE (-31.268). GLUE has higher annual earnings (EBITDA): 6.14M vs. RXRX (-524.77M). RXRX has more cash in the bank: 500M vs. GLUE (326M). GLUE has less debt than RXRX: GLUE (41.9M) vs RXRX (92.9M). GLUE has higher revenues than RXRX: GLUE (159M) vs RXRX (59.8M).
GLUERXRXGLUE / RXRX
Capitalization293M2.1B14%
EBITDA6.14M-524.77M-1%
Gain YTD-31.268-23.669132%
P/E Ratio39.75N/A-
Revenue159M59.8M266%
Total Cash326M500M65%
Total Debt41.9M92.9M45%
TECHNICAL ANALYSIS
Technical Analysis
GLUERXRX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 22 days ago
84%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VEXMX145.08N/A
N/A
Vanguard Extended Market Index Investor
GCBUX35.38N/A
N/A
Green Century Balanced Institutional
HRINX52.76N/A
N/A
Harbor International Administrative
GSELX67.10N/A
N/A
Goldman Sachs US Equity Insights Instl
CAABX25.53N/A
N/A
ClearBridge Sustainability Leaders C

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with EYPT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
+0.63%
EYPT - GLUE
47%
Loosely correlated
+14.81%
IMNM - GLUE
44%
Loosely correlated
-2.69%
ATXS - GLUE
43%
Loosely correlated
-1.91%
CRSP - GLUE
42%
Loosely correlated
+1.88%
RXRX - GLUE
42%
Loosely correlated
-1.15%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been closely correlated with CRSP. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-1.15%
CRSP - RXRX
72%
Closely correlated
+1.88%
BEAM - RXRX
64%
Loosely correlated
-2.27%
ABSI - RXRX
61%
Loosely correlated
-1.78%
ABCL - RXRX
59%
Loosely correlated
+3.26%
PRME - RXRX
57%
Loosely correlated
-1.63%
More